Detalles de la búsqueda
1.
NCCN Guidelines® Insights: Prostate Cancer, Version 3.2024.
J Natl Compr Canc Netw
; 22(3): 140-150, 2024 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38626801
2.
Accelerator-Based Production of Scandium Radioisotopes for Applications in Prostate Cancer: Toward Building a Pipeline for Rapid Development of Novel Theranostics.
Molecules
; 28(16)2023 Aug 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-37630292
3.
The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups.
Prostate
; 82(13): 1237-1247, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35675470
4.
Comparison of out-of-pocket costs and adherence between the two arms of the prospective, randomized abiraterone food effect trial.
Support Care Cancer
; 30(3): 2803-2810, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34845502
5.
Prevalence of potential interactions of medications, including herbs and supplements, before, during, and after chemotherapy in patients with breast and prostate cancer.
Cancer
; 127(11): 1827-1835, 2021 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33524183
6.
A prospective clinical and transcriptomic feasibility study of oral-only hormonal therapy with radiation for unfavorable prostate cancer in men 70 years of age and older or with comorbidity.
Cancer
; 127(15): 2631-2640, 2021 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33882144
7.
Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses.
J Urol
; 205(5): 1361-1371, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33356529
8.
Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen.
J Pharmacol Exp Ther
; 374(3): 438-451, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32554434
9.
Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer.
Prostate
; 79(15): 1752-1761, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31497882
10.
A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors.
Oncologist
; 24(9): 1151-e817, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31171735
11.
Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).
Invest New Drugs
; 36(5): 919-926, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30083962
12.
Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial.
Prostate
; 77(4): 385-395, 2017 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-27862097
13.
14.
Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study.
Prostate
; 76(3): 286-93, 2016 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26493492
15.
16.
The pluripotency factor Nanog is directly upregulated by the androgen receptor in prostate cancer cells.
Prostate
; 74(15): 1530-43, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25175748
17.
National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making.
Cancer
; 120(10): 1491-8, 2014 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-24523016
18.
Quantitative characterization of androgen receptor protein expression and cellular localization in circulating tumor cells from patients with metastatic castration-resistant prostate cancer.
J Transl Med
; 12: 313, 2014 Nov 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-25424879
19.
Hormonal Therapy and Radiation Therapy in Prostate Cancer: 5-Year Outcomes From a Trial Evaluating Combined Androgen Blockade With 5-Alpha Reductase Inhibitors as an Alternative to Gonadotropin Releasing Hormone Agonists.
Clin Genitourin Cancer
; 22(4): 102103, 2024 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-38781786
20.
A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer.
Clin Cancer Res
; 30(11): 2384-2392, 2024 Jun 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38536082